We recently compiled a list of the 10 Hottest Mid-Cap Stocks So Far in 2025. In this article, we are going to take a look at ...

Inari’s catalog includes the catheter-based FlowTriever and ClotTriever systems for mechanically removing blood clots in cases of pulmonary embolism and deep vein thrombosis, respectively.

The deal for Inari bolsters Stryker's efforts to build out its offerings to treat a condition called venous thromboembolism, where a blood clot forms in a vein, and other vascular diseases. Under the ...

Inari Medical stock skyrocketed Monday afternoon and again Tuesday morning after a report that it was close to being acquired by Stryker proved to be true, with the companies announcing the deal after ...

The deal for Inari bolsters Stryker’s efforts to build out its offerings to treat a condition called venous thromboembolism, where a blood clot forms in a vein, and other vascular diseases. Under the ...

The deal for Inari bolsters Stryker's efforts to build out its offerings to treat a condition called venous thromboembolism, where a blood clot forms in a vein, and other vascular diseases.

Medical devices behemoth Stryker agreed to buy Inari Medical for $4.9 billion. Inari stock catapulted Tuesday on the news.

Inari shareholders are getting a fair price relative ... risks and costs of thrombolytic therapy (drugs meant to break up clots) and a growing database on the safety and efficacy of mechanical ...

Inari Medical Inc (NASDAQ:NARI) makes medical devices to treat blot clots in veins and their main products are designed to remove clots from deep veins and pulmonary arteries without using clot ...

The deal for Inari bolsters Stryker’s efforts to build out its offerings to treat a condition called venous thromboembolism, where a blood clot forms in a vein, and other vascular diseases.

Despite a lackluster performance from Wall Street’s major indices, 10 companies demonstrated notable resilience.